http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
-
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
-
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
-
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
-
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte receives Medicare coverage for bladder cancer monitoring test
-
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
-
Veracyte Announces First Quarter 2026 Financial Results
-
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
-
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
-
Veracyte appoints Kevin Haas as chief development and technology officer
-
Veracyte Names Kevin Haas as Chief Development and Technology Officer
-
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
-
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
-
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
-
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte Announces Third Quarter 2025 Financial Results
-
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
-
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
-
Veracyte biomarker predicts hormone therapy benefit in prostate cancer
-
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
-
Veracyte to present prostate cancer biomarker data at ASTRO 2025
-
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
-
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
-
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
-
Veracyte study shows Decipher test predicts chemotherapy benefit
-
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
-
Veracyte completes enrollment for lung cancer test clinical trial
-
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
-
Veracyte Announces Second Quarter 2025 Financial Results
-
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
-
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
-
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte Announces First Quarter 2025 Financial Results
-
Veracyte (VCYT) Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
-
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
-
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
-
Veracyte (VCYT) Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
-
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
-
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
-
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
-
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
-
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
-
Veracyte to Participate in Upcoming Investor Conferences
-
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
